Aarti Pharmalabs Limited — Investor Meet, 16-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Pharmalabs has announced a board meeting to consider the financial results for the quarter and half-year. Q4 revenue grew 11% YoY to Rs. 564 Cr, with EBITDA up 24% at Rs. 146 Cr and margins expanding to 26%. PAT surged 35% to Rs. 88 Cr, while full-year PAT rose 26% to Rs. 272 Cr. Strong cash flow of Rs. 332 Cr supports capacity and R&D investments. Xanthine derivatives and API intermediates dominate revenue, with CDMO/CMO poised for 30-40% growth in FY26. Expansion projects targeting FY26-27 ramp-up and product innovation remain key, alongside a Rs. 400-450 Cr CAPEX plan. Management is optimistic on pricing stability and order book visibility, adopting a cautious yet confident growth outlook.